GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zealand Pharma A/S ZEAL.CO · DKK

Health Care · Nasdaq Copenhagen · 🇩🇰 Denmark

Compare

245.00

+5.20%

Close of 9 Nov 2026, in DKK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

24 analysts, 1 Feb 2026. The analysts' own views, not ours.

  • 7Strong buy
  • 13Buy
  • 3Hold
  • 1Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Feb 2026. Not our view.

Last close 245.00Average target 719.24

Low
404.00
Average
719.24
Median
663.00
High
1,176.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
RevenueDKK 4.75bnDKK 4.46bnDKK 1.74bnDKK 1.77bnDKK 2.77bn
Revenue, highestDKK 5.23bnDKK 7.16bnDKK 4.87bnDKK 2.59bnDKK 4.05bn
Revenue, lowestDKK 4.47bnDKK 1.30bnDKK 201.3mDKK 1.05bnDKK 1.64bn
Earnings per share26.408.86-38.39-23.32-15.11
Earnings per share, highest31.6351.4013.01-10.93-7.08
Earnings per share, lowest18.42-45.47-66.86-37.40-24.23
Analysts13151155

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Forecast0.92-8.85-8.29-8.26113.92-0.66-5.37-3.63
Reported55.34-5.58-1.11-5.75107.61-4.75-4.12-3.77
Difference+5889.2%+37.0%+86.6%+30.4%-5.5%-623.1%+23.2%-4.0%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

5 / 10

Revenue growth 47.6% a year over 10 years. Return on equity 43.5%.

Model fair value

204.55

From earnings 204.55, from revenue 15,451.75.

Piotroski score

4 / 9

A nine-point test of financial strength, for 31 Dec 2024.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.